Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
2.14M
-
Shares change
-
+74.5K
-
Total reported value, excl. options
-
$869M
-
Value change
-
+$30.4M
-
Number of buys
-
10
-
Number of sells
-
-4
-
Price
-
$406.89
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q4 2023
20 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q4 2023.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.14M shares
of 257M outstanding shares and own 0.83% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (22.3M shares), BlackRock Inc. (21.9M shares), Capital World Investors (21.8M shares), FMR LLC (13M shares), STATE STREET CORP (12.1M shares), ALLIANCEBERNSTEIN L.P. (7.04M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.89M shares), GEODE CAPITAL MANAGEMENT, LLC (5.67M shares), JPMORGAN CHASE & CO (5.62M shares), and WELLINGTON MANAGEMENT GROUP LLP (5.23M shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.